Streetbeat News

IMVT

Immunovant, Inc.

https://immunovant.com

Industry

Biotechnology

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Open

19.40

Mkt cap

3.3B

Volume

911K

High

19.52

P/E Ratio

-7.45

52-wk high

35.97

Low

18.70

Div yield

N/A

52-wk low

17.65

Immunovant (NASDAQ:IMVT) has received positive ratings from analysts in the last quarter, with 6 bullish and 7 somewhat bullish ratings, and no bearish sentiments. The average 12-month price target for IMVT is $41.69, with a high of $57.00 and a low of $30.00. This target has increased by 45.21% over the past month, indicating a positive outlook from analysts.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

Truist Securities analyst Robyn Karnauskas has reaffirmed a Buy rating on Immunovant (NASDAQ:IMVT) and increased the price target from $30 to $48.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 4:37 pm

Immunovant (NASDAQ:IMVT) reported its Q2 earnings, beating estimated earnings by 6.25% with an EPS of $-0.45 versus an estimate of $-0.48. However, revenue was down $0 from the same period last year. Last quarter, the company missed on EPS by $0.12, which was followed by a 0.67% increase in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 12:30 pm

Immunovant reported Q2 losses of $(0.45) per share, beating the analyst consensus estimate of $(0.48) by 6.25%. This is a 9.76% decrease over losses of $(0.41) per share from the same period last year. The company's pro forma cash and cash equivalent stands at $737M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:24 pm

Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Immunovant (NASDAQ:IMVT) and raises the price target from $28 to $57.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 3:46 pm

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Immunovant (NASDAQ:IMVT) and raises the price target from $29 to $47.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 10:55 am

Cantor Fitzgerald analyst Louise Chen maintains an Overweight rating on Immunovant (NASDAQ:IMVT) and raises the price target from $30 to $45.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:42 pm

Immunovant's stock has been upgraded from Neutral to Buy by UBS, with the price target raised from $18 to $55. This has resulted in Immunovant shares trading higher.

Portfolio Pulse from Bill Haddad

October 13, 2023 | 3:42 pm

UBS analyst Colin Bristow has upgraded Immunovant (NASDAQ:IMVT) from Neutral to Buy and raised the price target from $18 to $55.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 9:48 am

Immunovant (NASDAQ:IMVT) has received mostly bullish ratings from analysts in the last quarter, with no bearish or indifferent ratings. The average 12-month price target for the stock, according to 14 analysts, is $34.14, which has increased by 16.4% over the past month.

Portfolio Pulse from Benzinga Insights

October 09, 2023 | 4:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.